MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Vericel Corp Company Profile (NASDAQ:VCEL)

Consensus Ratings for Vericel Corp (NASDAQ:VCEL) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $12.00 (447.95% upside)

Analysts' Ratings History for Vericel Corp (NASDAQ:VCEL)
Show:
DateFirmActionRatingPrice TargetActions
4/5/2016Needham & Company LLCReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Bank of AmericaDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2016Ladenburg ThalmannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2015Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Vericel Corp (NASDAQ:VCEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/10/2016Q116($0.25)($0.08)$11.60 million$14.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.15)($0.28)$17.36 million$15.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2015Q315($0.21)($0.26)$10.50 million$11.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.13)($0.16)$11.31 million$13.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.14)($0.27)$11.10 million$10.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2015Q414($0.47)($0.17)$10.70 million$14.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.66)($0.52)$6.73 million$9.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($1.59)($0.94)$4.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014Q114($0.92)($1.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($1.34)($0.97)$0.02 million$0.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($2.02)($0.06)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.19)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Vericel Corp (NASDAQ:VCEL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Vericel Corp (NASDAQ:VCEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Vericel Corp (NASDAQ:VCEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/28/2016Consonance Capital ManagementMajor ShareholderSell120,000$5.39$646,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Daniel OrlandoCOOBuy9,804$2.55$25,000.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Dominick ColangeloCEOBuy20,000$2.55$51,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Vericel Corp (NASDAQ:VCEL)
DateHeadline
05/31/16 07:32 PMIs Selling Stock Like Vericel Corp After This Multiple Bottom Winning Strategy? - HNN - Is Selling Stock Like Vericel Corp After This Multiple Bottom Winning Strategy?HNNThe stock of Vericel Corp (VCEL) shows a multiple bottoms pattern with $2.46 target or 12.00% below today's $2.80 share price. The 6 months chart pattern indicates high risk for the $66.54 million company. It was reported on Jun, 1 by Finviz.com. If ...
05/30/16 09:08 PMVericel Corporation (NASDAQ:VCEL) Shorts Decreased by 63.64% After Short Covering - HNN - Vericel Corporation (NASDAQ:VCEL) Shorts Decreased by 63.64% After Short CoveringHNNThe stock of Vericel Corporation (NASDAQ:VCEL) registered a decrease of 63.64% in short interest. VCEL's total short interest was 158,800 shares in May as published by FINRA. Its down 63.64% from 436,800 shares, reported previously. With 194,000 ...Vericel Corporation (NASDAQ:VCEL) 1-Year High At $6.69Investor Newswireall 2 news articles »
05/29/16 01:33 PMHold Calls Count For Vericel Corporation (NASDAQ:VCEL) At 0 - Investor Newswire - Hold Calls Count For Vericel Corporation (NASDAQ:VCEL) At 0Investor NewswireVericel Corporation (NASDAQ:VCEL) has a total of 1 Strong Buy recommendations and 0 Strong Sell advises as of 2016-05-28. The rating procedure used by Zacks gives scores to firms on a narrow 1-5 scale. A score close to 1-2 band is a Buy call, a score ...and more »
05/23/16 11:59 AMVericel Corp. :VCEL-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/10/16 06:48 AMVericel Reports First-Quarter 2016 Financial Results - [at noodls] - Total Revenues of $14.1 Million Reported for the Quarter Carticel and Epicel Revenues Increase 31% versus First Quarter 2015 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 10, 2016 ...
05/06/16 03:17 PMVERICEL CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
04/27/16 03:51 PMVericel to Host First-Quarter 2016 Earnings Webcast and Conference Call on May 10, 2016 - [at noodls] - CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, ...
04/26/16 03:37 PMVERICEL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement -
04/08/16 07:47 AMVericel to Present at 15th Annual Needham Healthcare Conference - [at noodls] - CAMBRIDGE, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, ...
04/04/16 01:44 PMUPDATE 1-Vericel stem cell heart failure therapy cuts deaths -study - April 4 (Reuters) - A stem cell therapy developed by Vericel Corp helped reduce deaths and hospitalizations in advanced heart failure patients, according to data from a midstage study, potentially...
04/04/16 01:25 PM​Last month’s big stock spike at Vericel cut in half by further trial data -
04/04/16 11:18 AMVericel stem cell therapy cuts heart failure death, hospitalization-study - April 4 (Reuters) - A stem cell therapy developed by Vericel Corp helped reduce deaths and hospitalizations in advanced heart failure patients, according to data from a midstage study, potentially...
04/04/16 11:00 AMResults from Vericel's Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet - [at noodls] - CAMBRIDGE, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, ...
03/28/16 08:46 AMVericel Reports Publication of Trial Rationale, Study Design for Phase 2b ixCELL-DCM Trial of Ixmyelocal-T for Heart Failure Due to Ischemic Dilated Cardiomyopathy - Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the publication of the clinical trial rationale and study design for the company's Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM) in the journal Cell Transplantation. On March 10, 2016, Vericel announced that the ixCELL-DCM trial ...Full story available on Benzinga.com
03/10/16 09:43 AMUPDATE 1-Vericel's heart drug successful in mid-stage study - March 10 (Reuters) - Vericel Corp said its experimental drug reduced death, hospitalizations and emergency visits in patients, who are at risk of a heart failure, in a mid-stage study, sending its...
03/10/16 08:23 AMVericel Corp's heart drug meets main goal in mid-stage study - March 10 (Reuters) - Vericel Corp said its experimental heart drug met the main goal of reducing death, hospitalizations and emergency visits in patients in a mid-stage study.
02/26/16 12:55 PMWatch List for Traders: Transocean Ltd., Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), Vale S.A. ... - Gaining Green (press release) (registration) (blog) - Watch List for Traders: Transocean Ltd., Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), Vale S.A. ...Gaining Green (press release) (registration) (blog)Vericel Corporation (NASDAQ: VCEL) announced that the U.S. Food and Drug Administration has approved the Company's Humanitarian Device Exemption (HDE) supplement for Epicel (cultured epidermal autografts) to revise the labeled indications of use ...
02/26/16 12:55 PMVericel to Present at Canaccord Genuity Investor Conference - EIN News (press release) - Vericel to Present at Canaccord Genuity Investor ConferenceEIN News (press release)24, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the Canaccord Genuity ...
02/24/16 03:05 PMVericel to Present at Canaccord Genuity Investor Conference - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 24, 2016-- Vericel Corporation, a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will ...
02/22/16 07:30 AMVericel Announces FDA Approval of Epicel HDE Supplement - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 22, 2016-- Vericel Corporation, a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that the ...
01/23/16 07:10 PMVericel Corporation (NASDAQ:VCEL) Analyst Rating Update - Investor Newswire - Vericel Corporation (NASDAQ:VCEL) Analyst Rating UpdateInvestor NewswireWall Street analysts polled by Zacks Research have given Vericel Corporation (NASDAQ:VCEL) a rating of 2 on a consensus basis. Using a simplified scale where 1 is a Strong Buy and 5 a Strong Sell, this is the average number of the 2 brokerages surveyed.and more »
01/21/16 12:38 PMBioLargo Closes Financing To Advance Its Novel Wound Care Products - SECFilings.com - BioLargo Closes Financing To Advance Its Novel Wound Care ProductsSECFilings.comVericel Corporation (NASDAQ: VCEL) Vericel Corporation is a stem cell company developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy ...and more »
01/05/16 09:02 AMVericel Moving Up Following Submission Of Biologics Licence Application To The FDA -
01/04/16 03:16 PMVERICEL CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
01/04/16 03:10 PMVericel Submits Biologics License Application to the FDA for MACI for the Treatment of Cartilage Defects in the Knee - [at noodls] - CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, ...
12/18/15 07:01 AMVERICEL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, -
12/16/15 01:10 PMVericel Corp. Earnings Analysis: Q3, 2015 By the Numbers -
12/09/15 11:27 AMVericel Submits HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel - [at noodls] - CAMBRIDGE, Mass., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, ...
12/08/15 12:18 PMVERICEL CORP Financials -
11/25/15 05:43 AMHedge Fund Sentiment Is Stagnant On Vericel Corp (VCEL) -
11/13/15 10:32 AMVERICEL CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
11/13/15 07:00 AMVericel Corp Earnings Call scheduled for 8:00 am ET today -
11/13/15 06:46 AMVericel Reports Third-Quarter 2015 Financial Results - [at noodls] - Total Revenues of $11.3 Million Reported for the Third Quarter Carticel and Epicel Revenues Increase 19% Compared to Third Quarter of 2014 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., ...
About Vericel Corp

Vericel Corp logoVericel Corporation (Vericel), formerly Aastrom Biosciences, Inc. develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA). The Company is also developing ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The Company has two cell manufacturing facilities in Cambridge, Massachusetts and Copenhagen, Denmark. Vericel also operates a centralized cell manufacturing facility in Ann Arbor, Michigan.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VCEL
  • CUSIP:
Key Metrics:
  • Previous Close: $2.19
  • 50 Day Moving Average: $2.66
  • 200 Day Moving Average: $2.79
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $49.58M
  • Current Quarter EPS Consensus Estimate: $-0.79 EPS
Additional Links:
Vericel Corp (NASDAQ:VCEL) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha